Edition:
India

Carmat SA (ALCAR.PA)

ALCAR.PA on Paris Stock Exchange

23.35EUR
4 Dec 2020
Change (% chg)

€0.10 (+0.43%)
Prev Close
€23.25
Open
€23.50
Day's High
€23.50
Day's Low
€23.00
Volume
17,261
Avg. Vol
11,202
52-wk High
€23.90
52-wk Low
€10.10

Summary

Name Age Since Current Position

Jean-Pierre Garnier

72 2018 Chairman of the Board

Stephane Piat

2017 Chief Executive Officer, Director

Pascale d'Arbonneau

2019 Chief Financial Officer, Head of investor relations

Marc Grimme

Technical Director

Francesco Arecchi

2017 Director - Marketing

Raouia Bouyanzer

Director - Human Resources

Thierry Dupoux

2018 Director - Quality

Alexandre Eleonore

2019 Industrial Director

Petrus Jansen

2009 Medical Director

Eric Richez

2014 Director - Development

Karl Hennessee

2019 Director - Representative of Matra Defense

Antonino Ligresti

81 2016 Director - Representative of Sante Holdings SRL

Philippe Pouletty

60 2010 Director - Representative of Truffle Capital

Pierre Bastid

65 2018 Independent Director

Henri Lachmann

81 2010 Independent Director

Jean-Luc Lemercier

62 2017 Independent Director

Michael Mack

2017 Independent Director

Biographies

Name Description

Jean-Pierre Garnier

Dr. Jean-Pierre Garnier Ph.D. serves as Chairman of the Board of the Company. Jean-Pierre Garnier graduated from Louis Pasteur University (PhD in Pharmacology) and Stanford University (Master in Business Administration). He started his career in 1975 at the pharmaceutical company Schering-Plough where he held a number of management positions in Europe before becoming President of their American division. In 1990, he joined Smithkline Beecham Laboratories as President of the Pharmaceuticals Division and became President and CEO in 1999. In 2000, Jean-Pierre Garnier achieved the merge of two of the largest pharmaceutical groups (Smithkline Beecham and Glaxo Wellcome), to create GlaxoSmithKline (GSK), which he chaired until 2008. He was also Chairman of Actelion from 2011 to 2017. The Best Practice Institute has nominated Jean-Pierre Garnier as one of the world’s top 20 CEOs. He is an Officier de la Légion d’Honneur (Officer of the Legion of Honour) and Knight Commander of the Order of the British Empire.

Stephane Piat

Mr. Stephane Piat serves as Chief Executive Officer, Director of the Company. Stéphane Piat is an acknowledged specialist in the medical device business, particularly in the field of cardiology. Mr Piat started his career at Becton Dickinson European Headquarters as a Market Researcher in 1995. He was appointed European Platform Leader for Locoregional Anaesthesia five years later. In 2002, he joined Cordis, a Johnson & Johnson company, where he spent five years in several management positions ranging from Business Director France to European Marketing Director for Cardiology. In 2007, he moved to Abbott Vascular as General Manager for mid-size countries, EMEA, and two years later oversaw the integration of Evalve as the company’s General Manager EMEA, heading clinical and commercial development of a new interventional cardiology product, Mitraclip. In 2014, he led Global Market Development of the Abbott Vascular Structural Heart Division in San Francisco as Division Vice President. Mr Piat holds a master’s degree in Management Science from IAE Dijon School of Management, and a post-graduate degree in Quantitative Marketing from ESA business school in Grenoble.

Pascale d'Arbonneau

Ms. Pascale d'Arbonneau serves as Chief Financial Officer, Head of investor relations of the Company. A graduate of the ESCP business school and holder of a DEA in Management Control and a Postgraduate Diploma in Finance and Accounting, Pascale d’Arbonneau is also a lecturer at Paris Diderot University. She began her career in 1989 as an auditor at Coopers & Lybrand (now PWC) before entering the pharmaceutical industry as Head of Finance & IT France at Johnson & Johnson – MSD (1995-1999). She spent most of her career (1999-2016) at GlaxoSmithKline (GSK). She joined as Director, Head of Controlling & Finance Partnering, and then held a number of senior positions within the Group (Vice President & Finance Controller, Pharma Europe from 2006 to 2010, Vice President & Area Finance Director, Western Europe from 2010 to 2014) before becoming Vice President Compliance and Control Integration for all business units worldwide. Before joining CARMAT at the end of 2018, Pascale d’Arbonneau was Executive Director of the Econocom International B.V. family office.

Marc Grimme

Mr. Marc Grimme serves as Technical Director of the Company. Marc Grimmé has been the technical lead on the programme to develop the Carmat bioprosthetic heart. He began his career in 1991 at MBDA France, where he worked on a range of issues linked to the development of mission-critical electronics, from upstream studies and the design phase to production commissioning. Marc Grimmé is a graduate of the Institute Supérieur d’Electronique et du Numérique (ISEN).

Francesco Arecchi

Mr. Francesco Arecchi serves as Director - Marketing of the Company. A marketing professional with strong experience in global leading companies within the healthcare industry, Francesco Arecchi joins Carmat in September 2017. Francesco Arecchi spent most of his career in Life Sciences companies such as Johnson & Johnson and Abbott, where he holds a number of positions from sales to marketing in Cardiology breakthrough technology products such as Cypher and MitraClip. Prior to joining Carmat, he stood as Product Manager EMEA Structural Heart at Abbott. Francesco Arecchi is a biomedical engineer and graduated from Politecnico di Milano (Italy) with an MBA from Rotterdam School of Management (Netherlands).

Raouia Bouyanzer

Ms. Raouia Bouyanzer serves as Director - Human Resources of the Company. Raouia has almost 16 years of experience in payroll and human resources management. She began her career in an accounting firm in 1998. In 2001, Raouia joined Morgan Stanley, where she held more than 9 years in several positions in social management control, payroll and human resources. Raouia holds a master’s degree in HR from ESSEC Business School and holds a degree in accounting and finance (2001).

Thierry Dupoux

Mr. Thierry Dupoux serves as Director - Quality of the Company. Thierry Dupoux is a seasoned medical device professional with a strong and large expertise in Quality Assurance / Regulatory Affairs and R&D. Engineering Graduate from Ecole Centrale de Lyon (France), he has worked most of his career for Life Sciences companies such as General Electric where he became Supply Chain Quality & Compliance Manager for the plant of Buc (France) in his last position. In 2006, he joined Sorin Group, now named Liva- Nova, a world leader in Cardiac Surgery and Neuromodulation. Over the past 12 years at LivaNova, he held several senior positions in Quality Assurance, Regulatory Affairs and R&D. Prior to joining CARMAT, he was Vice President of Quality Assurance at LivaNova where he led the integration of the Quality Systems following the merger between Sorin Group and Cyberonics.

Alexandre Eleonore

Mr. Alexandre Eleonore serves as Industrial Director of the Company. Alexandre Eleonore is a confirmed industry expert with a strong background in operational management. He graduated from the Sevenans Polytechnic Institute, now UTBM (Université de Technologie Belfort-Montbéliard), and spent the first part of his career in leading automotive equipment manufacturers such as Faurecia and Plastic Omnium. After 10 years in this sector, he joined the Sorin group in 2009, which became Microport CRM, one of the world’s leading players in the treatment of cardiac rhythm disorders. He became Vice President Operations & Customer Service and implemented cost improvement plans, thanks to his knowledge of lean manufacturing and industrial process automation.

Petrus Jansen

Dr. Petrus Jansen serves as Medical Director of the Company. Dr Petrus “Piet” Jansen has 20 years management experience in the circulatory support device industry. He began his career in 1997 as Director of Clinical Research for the Novacor Division of Edwards Lifesciences, a US company specializing in patient-focused medical innovations for structural heart disease. In 2001, he was appointed Vice President at Jarvik Heart Inc in New York, where he was responsible for the clinical programs. From 2004 to 2009, he was Chief Medical Officer with World Heart Corporation. Dr Jansen holds a PhD in medicine from the University of Amsterdam and graduated as medical doctor from Radboud University Nijmegen, both in the Netherlands.

Eric Richez

Mr. Eric Richez serves as Director - Development of the Company. Eric Richez joined CARMAT in September 2014 after a career in the European medical device industry. He has over 13 years’ experience in sales & marketing with Thoratec, a global leader in ventricular assistance devices, where he served as Sales & Marketing Director from 2002 to 2011 and Sales Director EMEA from 2011 to 2013. He then joined CircuLite, a company developing a circulatory support system to treat chronic heart failure, as Sales Director for Southern Europe. Mr Richez holds a degree in Mathematics and training in Business & Management and Sales Force Management.

Karl Hennessee

Mr. Karl Hennessee serves as Director - Representative of Matra Defense of the Company. Karl Hennessee, Senior Vice-President of Airbus, has 25 years of experience in law, economics and regulation. He worked, in Europe and in the United States, as a business lawyer on some of the most important files for a very large company in the energy sector, then as Secretary General of this same company. In addition to his management functions at Airbus, Karl Hennessee is the Chairman of the Board of Directors of the International Arbitration Tribunal within the International Chamber of Commerce. He also sits on the Board of Directors of many other non-profit organizations. He also lectures and regularly publishes articles on law and regulations.

Antonino Ligresti

Dr. Antonino Ligresti serves as Director - Representative of Sante Holdings SRL of the Company. Dr. Antonino Ligresti began his career in the Medical Clinic at Milan University and at the city’s Fatebenefratelli Hospital. In 1979, following the gradual acquisition of several high-profile establishments in Lombardy, he created Italy’s first private hospital group, acknowledged for the quality of its services and patient-centric care, as well as its ties with teaching and academic research. Dr Ligresti joined the Générale de Santé board of directors in 2003 and became its chairman a year later. He was also instrumental in creating the European Oncology Institute. Dr. Ligresti is a qualified physician and surgeon, specialising in cardiology and internal medicine.

Philippe Pouletty

Dr. Philippe Pouletty M.D. serves as Director - Representative of Truffle Capital of the Company. Dr. Philippe Pouletty is a pioneer in biotechnology and medical devices. He founded SangStat in 1988, a company specialising in organ transplant therapy, listed on the NASDAQ, then Conjuchem in 1993, a biotech firm specialised in developing next-gen medicines from therapeutic peptides, listed on the Toronto Stock Exchange. He is the co-founder and CEO of Truffle Capital, founder and Chairman of Deinove, a biotech company that develops compounds for industry from rare microorganisms, and Abivax, an innovative biotech firm that targets the immune system to eliminate viral and inflammatory diseases. Dr. Pouletty is also founder of Carbios, a green chemical company developing innovative enzyme processes to reshape the lifecycle of plastics, co-founder and board member of Pharnext, a leading biopharma company in combinatorial medicine, and Vexim, an innovative medical devices company, Chairman of Diaccurate, a biotech company specialising in immunomodulation, and board member at Myopowers, Biokinesis, Kephalios and all other companies in the Truffle Capital portfolio.

Pierre Bastid

Mr. Pierre Bastid serves as Independent Director of the Company. Former manager at Schneider Electric then Valeo, Pierre Bastid becomes in 1998 Vice President of Thomson Television Components France (Thomson Multimedia Group). In 2004, via the Magenta Participations structure, it successfully participated in the acquisition of Alstom Power Conversion, a group that later became Converteam Group, sold to General Electric in 2011. Since that date, Pierre Bastid manages his assets resulting from the sale of his shares of Converteam.

Henri Lachmann

Mr. Henri Lachmann serves as Independent Director of the Company. Henri Lachmann began his career in 1963 as an auditor at Arthur Andersen. Seven years later, he joined French metal company Strafor-Facom and became the company’s CEO in 1981. He has been a member of the board at Schneider Electric since 1996 and became the company’s CEO in 1999. He also held the position of Chairman of the Supervisory Board from 2006. Mr Lachmann graduated from HEC business school and is a qualified chartered accountant. He is Director and Vice-President of the Saint Joseph hospital / Marie Lannelongue hospital foundation.

Jean-Luc Lemercier

Mr. Jean-Luc Lemercier serves as Independent Director of the Company. Jean-Luc Lemercier draws on more than 30 years’ experience and acknowledged leadership in medical devices. During his career, he has held a number of key positions in the field of cardiology, notably at Johnson & Johnson Cordis from 1996 to 2008, where he created and headed the Structural Heart Disease division. Since 2017, he has been Corporate Vice President EMEA, Canada & Latin America at Edwards Lifescience. Mr Lemercier graduated in pharmacy from Claude Bernard Lyon 1 University.

Michael Mack

Dr. Michael Mack serves as Independent Director of the Company. Michael Mack is an internationally renowned cardiac surgeon with extensive experience in the introduction of medical devices and innovative procedures for cardiovascular disease. He has authored more than 650 scientific publications and has received the Presidential Citation from the American College of Cardiology (ACC) and the Transcatheter Cardiovascular Therapeutics (TCT) Lifetime Achievement Award. Dr Mack is a graduate of Boston College, St Louis University and the University of Texas Southwestern Medical School. He is also the Director of the Cardiovascular department for pharmaceutical firm Baylor Scott & White Health, a Director on the American Board of Thoracic Surgery and a member of the FDA Medical Device Epidemiology Network Initiative (MDEpiNet) Advisory Committee.